Dendritic cells (DC) constitute a unique system of cells that induce, sustain and regulate
immune responses. Distributed as sentinels throughout the body, DC are poised to capture …

During the last decade use of dendritic cells (DC) has moved from murine and in vitro
studies to clinical trials as adjuvant in cancer immunotherapy. Here they function as delivery …

As crucial antigen presenting cells, dendritic cells (DCs) play a vital role in tumor
immunotherapy. Taking into account the many recent advances in DC biology, we discuss …

Recent progress in the approach towards immunotherapy of cancer consists in molecular
definition of tumor antigens, new tools for phenotypical and functional characterization of …

Human tumors express a number of protein antigens that can be recognized by T cells, thus
providing potential targets for cancer immunotherapy. Dendritic cells (DCs) are rare …

Current active immunotherapy trials have shown durable tumor regressions in a fraction of
patients. However, the clinical efficacy of current vaccines is limited, possibly because …

Dendritic cells (DC) are the most potent antigen presenting cells (APC) and the only ones
capable of presenting novel antigens to naïve T-cells. Large numbers of DC can be …

Dendritic cells (DCs) are considered as professional antigen presenting cells (APCs),
containing a variety of subsets, that can be resident in organs or migrating among the …

Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines,
tested different vaccine preparations, but they did not always induce sufficient acquired …

T cells can reject established tumors when adoptively transferred into patients, thereby
demonstrating that the immune system can be harnessed for cancer therapy. However, such …